Pancreatic cancer is one of the most aggressive solid tumors with limited treatment success. CAR-T cell therapy in China is being actively researched as a new immunotherapy approach, offering potential hope through early-stage clinical trials and innovative engineered T-cell technologies.
CLDN18.2 has become one of the most promising therapeutic targets in pancreatic cancer. From bispecific antibodies and antibody-drug conjugates to CAR-T cell therapy, researchers are exploring innovative approaches that could transform treatment options for patients with this difficult-to-treat disease.
Solid tumors account for the majority of cancer cases worldwide and remain one of the greatest challenges in modern medicine. While significant advances have been made in surgery, chemotherapy, targeted
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.